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Objective: To determine in patients admitted with an acute exacerbation of chronic obstructive 
pulmonary disease (AE-COPD) the association between the isolation of potential pathogens in 
a conventional sputum culture and comorbidities.
Patients and methods: The ESMI study is a multicenter observational study. Patients with 
AE-COPD admitted to the Internal Medicine departments of 70 hospitals were included. The 
clinical characteristics, treatments, and comorbidities were gathered. The results of conventional 
sputum cultures were recorded.
Results: A total of 536 patients were included, of which 161 produced valid sputum and a 
potentially pathogenic microorganism was isolated from 88 subjects (16.4%). The isolation of 
Pseudomonas aeruginosa (30.7%) was associated with a greater severity of the lung disease 
(previous admissions [P= 0.026], dyspnea scale [P=0.047], post-broncodilator forced expira-
tory volume in 1 second (FEV
1
) [P=0.005], and the BODEx index [P=0.009]); also with higher 
prevalence of cor pulmonale (P=0.017), heart failure (P=0.048), and cerebrovascular disease 
(P=0.026). Streptococcus pneumoniae (26.1%) was associated with more comorbidity according 
to number of diseases (P=0.018); notably, peripheral artery disease (P=0.033), hypertension 
(P=0.029), dyslipidemia (P=0.039), osteoporosis (P=0.0001), and depression (P=0.005).
Conclusion: Patients with AE-COPD and P. aeruginosa present higher severity of COPD, while 
those with S. pneumoniae present greater comorbidity. The potentially pathogenic microorgan-
ism obtained in the sputum culture depends on the associated comorbidities.
Keywords: chronic obstructive pulmonary disease, comorbidities, hospitalization, sputum 
culture, etiology of exacerbations
Introduction
Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) have a 
great impact on health status,1 disease progression,2 and prognosis.3
Up to 50%–70% of AE-COPD can be attributed to respiratory infections by viruses 
or bacteria, even more in the most severe patients.4 Finding a purulent sputum sug-
gests, but does not prove, a bacterial etiology, since 25%–50% of COPD patients are 
colonized by potentially pathogenic microorganisms (PPM).5 Bacterial colonization 
has been associated with the frequency and severity of COPD exacerbations.6
Most guidelines recommend the use of antibiotics whenever two or more of the 
Anthonisen’s criteria,7 ie, increased dyspnea, increased sputum volume, and increased 
sputum purulence, are met. Nevertheless, sputum purulence seems to be the main 
factor associated with infection.8,9
The choice of antimicrobial agent depends on the suspected microorganism, 
based on the clinical circumstances,10 the severity of the COPD,11 and the presence 
of comorbidities (diabetes mellitus, liver cirrhosis, chronic kidney failure, or heart 
disease), infections, or previous antibiotherapy.
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Even though the presence of comorbidities is associated 
with a higher risk of therapeutic failure and modifies the 
choice of antibiotic according to recommendations of sci-
entific societies,12,13 such indications are mainly based on 
expert opinion, not on prospective studies. Hence, studies 
are needed to prove whether the presence of comorbidities 
bears any relation to the microorganism causing AE-COPD 
and might help to choose an antibiotic treatment empirically. 
This way both therapeutic failure and occurrence of resistance 
could be reduced.
Our primary aim was to assess the comorbidities of 
patients admitted to Internal Medicine services and its asso-
ciation to bacteriological isolation through conventional 
sputum culture, seeking to obtain clinical features that might 
help a microbiological diagnosis.
Materials and methods
The ESMI (Spanish acronym for COPD in Internal Medicine 
Services) is an epidemiological multicenter research study, 
cross-sectional in the first stage and longitudinal later on. The 
inclusion period lasted a year (October 2009 to October 2010) 
and its methodology has been previously described else-
where.14 In brief, the ten first consecutive patients attended 
to in each of 70 participating hospitals for AE-COPD were 
studied, whether they required hospitalization or not. The 
main aim was to describe the comorbidities and their rela-
tion to mortality and hospital readmissions within the first 
3 months after discharge.
For this research, only patients admitted with a con-
firmed AE-COPD were included, since guidelines recom-
mend carrying out a sputum culture in this population, that 
usually presents with a severe or very severe exacerba-
tion along with therapeutic failure.15,16 In conclusion, this 
study was a multicenter, cross-sectional study conducted 
to identify isolated bacteria in the sputum of exacerbated 
COPD patients and to relate them to the comorbidities. The 
COPD diagnosis required spirometric confirmation (post-
bronchodilator FEV
1
/forced vital capacity (FVC) ,0.7). 
Patients admitted for causes other than AE-COPD and those 
who could not undergo the spirometry or did not meet the 
spirometric criteria were excluded.
All patients included were assessed during admission, 
and their clinical and functional data were gathered through 
a specifically designed questionnaire. The Charlson index17 
was used to asses comorbidities, without age adjustments 
and including COPD, as well as a number of other diseases 
not included in this index that we considered especially 
relevant, such as history of myocardial infarction, arterial 
hypertension, venous thromboembolic disease, arrhythmia, 
anemia, dyslipidemia, or osteoporosis.14
Other data gathered included body mass index, the modi-
fied Medical Research Council (mMRC) dyspnea scale,18 
the usual treatment prior to admission, basal gasometry at 
admission, and C-reactive protein (CRP). The functional 
status was also assessed, using Katz index19 at baseline. The 
BODEx index20 (replaces exercise capacity with exacerba-
tions) score was calculated.
Finally, conventional sputum samples were taken during 
the admission according to the usual clinical practice. The 
sputum was considered valid following the criteria of Murray 
and Washington.21
In order to compare clinical characteristics in relation to 
the sputum results, patients were divided according to the 
microorganism isolated in their culture, comparing them 
with the rest of the patients with a valid culture but different 
microorganism results.
Eventually, this resulted in the division of patients into 
three groups, and based on whether FEV
1
 is above or under 
50%,10,22 we grouped the patients depending on the isolation 
of Pseudomonas aeruginosa or Enterobacteriaceae (group 1); 
Streptococcus pneumoniae, Haemophilus influenzae or 
Moraxella catarrhalis (group 2); or non-potential pathogen 
microorganisms (nPPM) (group 3).
Statistical analysis
Qualitative variables are expressed as absolute frequency 
and percentages (%), and quantitative variables as mean 
and standard deviation in case of normal distribution, and 
as median otherwise. For the bivariate analysis, we used the 
chi-square test or Fisher’s exact test whenever it was required. 
To study the differences between averages, we used Student’s 
t-test or Mann–Whitney U-test whenever appropriate. The 
analysis was carried out with the SPSS 15.0 statistical pack-
age, and every analysis was based on the bilateral hypothesis 
with a statistical significance level under P,0.05.
The study was approved by the Clinical Trials Committee 
of the Hospital Mútua de Terrassa that acted as a coordinating 
center. All patients accepted taking part freely and signed an 
informed consent document.
Results
Out of a total of 679 identified patients, 606 were included 
in the ESMI study. Of these, 70 (11.5%) were discharged 
directly from Emergency Department, not requiring hospital-
ization in the ward, and were hence excluded. Compared with 
patients who did require hospitalization, those discharged 
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from Emergency Department were younger and had better 
pulmonary function and fewer comorbidities (P,0.001). 
Furthermore, it was possible to obtain a conventional sputum 
sample from a smaller percentage of this group (26.1% vs 
47.8%, P,0.05).
A sputum sample was obtained from 256 (47.8%) out of 
536 patients. The most frequent reasons for not obtaining 
it from the remaining 280 (52.2%) patients were that they 
could not expectorate (101 patients, 18.8%) and that they 
were not asked to during their hospitalization (172 patients, 
32.1%). In the case of seven other patients, the cause was not 
registered. Figure 1 shows the flowchart of participants.
Characteristics of patients
The clinical and demographic characteristics of patients are 
presented in Table 1. The mean age was 73.2 (9.5) years 
(range 41–94). In all, 486 (90.8%) were men, with an average 
post-bronchodilator % predicted FEV
1
 of 48.3 (15.7), and 
their average Charlson index score was 3.14 (2.0). Compared 
with the participants who did not produce sputum, the COPD 
patients who produced a sputum sample had a significantly 
higher smoking exposure, suffered more hospitalizations 
for AE-COPD in the previous year, and required long-term 
oxygen therapy (P,0.05).
Table 2 presents the characteristics of exacerbations. Prior 
to admission, systemic corticosteroids or antibiotics had been 
administered to 21.9% and 31.7% of subjects, respectively. 
Compared with the participants who did not produce sputum, 
the COPD patients who produced a sputum sample more 
frequently experienced an increase of expectoration, change 
of color in the sputum, and fever. Furthermore, their hospital 
stays were longer (P,0.05). The sputum was valid for culture 
in 161 patients. Compared with those who did not provide 
a sputum, they had shown symptoms prior to admission for 
more days (6.4 vs 5.2; P=0.038), they had higher CRP values 
(mg/L) in Emergency Department (63.2 vs 35; P=0.03) and 
their hospital stay was longer (10.9 vs 9.1 days; P=0.04).
Bacteriologic isolation
Out of 161 patients who provided a sputum sample that was 
valid for culture, saprophytic flora (nPPM) was isolated in 
73 (44.8%). The culture was positive for PPM in 88 of all 536 
AE-COPD cases who required hospitalization (16.4%). The 
most frequently isolated microorganism was P. aeruginosa 
in 27 (30.7%), followed by S. pneumoniae in 23 (26.1%), 
Enterobacteriaceae in 18 (20.4%), H. influenzae in 14 cases 
(15.9%), and finally M. catharrhalis in 6 (6.8%) (Figure 2).
Bacterial flora in the sputum and 
comorbidity
Table 3 presents the various comorbidities according to isola-
tion in sputum cultures. In Figure 3, we show the different 
characteristics of patients according to the microbiological 
diagnostic of the sputum culture.
????????????
???????????? ???????????????????? ????????????????????????????????
???????????? ??????????????????????????????
???????????????????????
?????????????????????????????????????
?????????????????????????????????????
??????????????? ?????????????????
????????????????????????????????????????
Figure 1 Flowchart of the patients.
Abbreviations: AE-COPD, acute exacerbation of chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Table 1 Characteristics of all study patients
Total (n=536) With sputum (n=256) Without sputum (n=280) P-value
age, mean ± SD, years 73.19±9.6 73.68±9.2 72.7±9.9 0.26
Male sex 486 (90.8) 234 (91.8) 252 (90) 0.48
BMI ± sD 27.4±4.8 27.3±4.5 27.6±5.1 0.40
smoking status
ex-smokers 506 (94.4) 246 (96.1) 260 (92.9) 0.10
never 30 (5.6) 10 (3.9) 20 (7.1)
Smoking history, mean ± SD, packs/year 56.6±27.5 59.3±26.5 54.1±28.3 0.03
First admission for ae-COPD 112 (20.9) 39 (15.2) 73 (26.2) 0.002
Hospitalized for AE previous year 394 (73.5) 199 (77.7) 195 (69.6) 0.03
Hospitalization for AE previous year, mean ± SD, number 1.6±1.6 1.8±1.66 1.4±1.6 0.006
Hospitalization for AE previous year, mean ± SD, days 14.6±17.0 17.3±18.3 12.1±15.3 ,0.001
Charlson index 3.1±2.0 3.2±2.02 3.05±1.99 0.29
Katz index 5.2±1.3 5.19±1.38 5.27±1.3 0.49
Dyspnea scale (mMRC) 2.3±1.1 2.4±1.05 2.32±1.13 0.37
Spirometry post-PBDa
FeV1 ± sD, ml 1,186±503 1,164±500 1,207±508 0.36
FVC ± sD, ml 2,243±840 2,241±807 2,244±872 0.97
FeV1/FVC ± sD 55.2±32.9 52.5±11.7 57.9±44.5 0.09
FeV1% ± sD 48.3±15.7 48.6±15.4 48.1±15.9 0.72
FVC% ± sD 68.5±18.5 68.8±18.5 68.5±18.6 0.83
COPD grade (gOlD)
Moderate (50–80) 176 (42.4) 81 (39.7) 95 (45) 0.14
severe (30–49) 190 (45.8) 103 (50.5) 87 (41.2)
Very severe (,30) 49 (11.8) 20 (9.8) 29 (13.7)
Treatment prior admission
Long-term oxygen therapy 220 (41) 119 (46.5) 101 (36.2) 0.02
CPaP 47 (8.8) 20 (7.8) 27 (9.7) 0.45
Notes: Data presented as absolute frequencies (percentage), or mean (standard deviation). aData of spirometric parameters of 415 patients (spirometry in the last 6 months). 
Bold font denotes statistical significance.
Abbreviations: BMI, body mass index; AE, acute exacerbation; mMRC, modified Medical Research Council; PBD, post-bronchodilator; GOLD, Global Obstructive Lung 
Diseases; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Table 2 Characteristics of the patients and the acute exacerbation
Total (n=536) With sputum (n=256) Without sputum (n=280) P-value
Symptoms of AE, n (%)
Increased dyspnea 530 (98.9) 251 (98) 279 (99.6) 0.11
Increased expectoration 382 (73.3) 211 (84.4) 171 (63.1) ,0.001
Change in the sputum 394 (75.6) 218 (87.2) 176 (64.9) ,0.001
Fever 191 (36.7) 117 (46.8) 74 (27.3) ,0.001
Anthonisen grade, n (%)
Class I
Class II
Class III
Laboratory data, mean ± sD
395 (73.8)
15 (2.8)
125 (23.4)
214 (83.6)
10 (3.9)
32 (12.5)
181 (64.9)
5 (1.8)
93 (23.4)
,0.001
CrP (mg/l) 49.2±82.6 53.4±87.4 44.9±77.7 0.39
Arterial blood analysis, mean ± sD
pO2 (mmhg) 60.1±16.7 59.8±16.8 60.5±16.8 0.65
pCO2 (mmhg) 47.6±13.5 47.72±14.2 47.43±12.8 0.82
hCO3 (mEq/L) 28.4±5.2 28.5±5.2 28.3±5.25 0.73
ph 7.39±0.07 7.4±0.08 7.39±0.07 0.25
Oral corticosteroids prior admission, n (%) 117 (21.9) 62 (24.2) 55 (19.7) 0.21
Antibiotics prior admission, n (%) 170 (31.7) 81 (31.6) 89 (31.8) 0.97
Days of clinical symptoms, mean ± sD 6.06±6.3 6.03±5.23 6.08±7.2 0.92
Length of stay, mean ± sD 9.3±7.5 10.3±7.02 8.4±7.9 0.004
Mortality during hospitalization, n (%) 8 (1.6) 6 (2.4) 2 (0.7) 0.16
Notes: Data presented as absolute frequencies (percentage), or mean (standard deviation). Bold font denotes statistical significance.
Abbreviations: AE, acute exacerbation; CRP, C-reactive protein; pO2, partial arterial oxygen pressure; pCO2, partial arterial carbon dioxide pressure; HCO3, bicarbonate.
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Patients with P. aeruginosa isolation in their sputum (27) 
more frequently had cor pulmonale (P=0.01), heart failure 
(P=0.04), and cerebrovascular disease (P=0.02). Also, these 
patients have a more severe (mean %FEV
1
 41.1 vs 49.1; 
P=0.005), higher BODEx index scores (6 vs 4.7; P=0.008), 
greater probability of having required admissions for AE-
COPD during the previous year (92.6% vs 71.6%; P=0.02), 
greater dyspnea according to the mMRC scale (2.7 vs 2.3; 
P=0.047), a higher number of exacerbations (according to 
stratification used in BODE; P=0.01), greater purulence of 
sputum at admission (P=0.02), and they more frequently 
used inhaled corticosteroids (100% vs 88%, P=0.04). The 
number of hospitalizations during the previous year (2.3 
vs 1.7; P=0.07) and of days of hospital stay (14.5 vs 10.2; 
P=0.05) were higher, but not significantly.
Patients with S. pneumoniae isolation had more comor-
bidities (5.9 vs 2.7; P=0.002), and greater probability of hav-
ing a Charlson index above three, though without statistical 
significance (52.2% vs 32.6%; P=0.07). The comorbidities 
more frequently associated with S. pneumoniae isolation 
were hypertension (P=0.04), dyslipidemia (P=0.03), periph-
eral vascular disease (P=0.03), osteoporosis (P=0.000), and 
depression (P=0.005). According to the characteristics of 
the present exacerbation, these patients had fewer previous 
?????
?????
?????
?????
????
?? ?? ???? ?? ??
Figure 2 Potential pathogen microroganism isolated in sputum during exacerbation 
of COPD.
Abbreviations: Pa, Pseudomonas aeruginosa; sP, Streptococcus pneumoniae; eB, 
Enterobacteriaceae; HI, Haemophilus influenzae; MC, Moraxella catharrhalis.
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days with symptoms (4.7 vs 6.7; P=0.01), and according to 
the Anthonisen criteria greater increase of sputum (P=0.02) 
and of purulence (P=0.04). As for the previous treatment, 
they presented more use of β-lactams prior to admission 
(P=0.02) and statins (P=0.002). According to the treatment 
during the exacerbation, there was greater use of diuretics 
(P=0.02). There is a tendency to a greater smoking history 
measured in packs/year (48.5 vs 59.5; P=0.06) and a longer 
span of time between exacerbation and COPD diagnosis, in 
years (12.2 vs 9.1; P=0.04).
Patients with Enterobacteriaceae isolation were younger 
(66.6 vs 74 years; P=0.04), had lesser functional impairment 
according to Katz index (5.6 vs 5.2; P=0.04), and more 
frequently presented with mild liver disease (P=0.01). Also 
notable, they showed less fever (P=0.02) and comorbidities 
(arterial hypertension [P=0.022], dyslipidemia [P=0.007], 
and peripheral vascular disease [P=0.046]). Comparing the 
treatment of this group of patients, we found the less use of 
statins (P=0.001) and a greater need of continuous positive 
airway pressure (P=0.01). Finally, no differences appear as 
for AE-COPD severity factors.
Comparing patients with H. influenzae isolation in the 
sputum with the non-H. influenzae group, their differential 
characteristics are a greater presence of peptic ulcer (P=0.04) 
and atrial fibrillation (P=0.01). Comparing treatments, they 
have lesser need of home oxygen therapy (P=0.03). They also 
required fewer days of hospital stay over the previous 12 months 
(P=0.04) and in the current AE-COPD admission (P=0.02).
No differences are clear when comparing patients with 
M. catharralis isolation in the sputum with the remainder.
Finally, if we compare patients with nPPM isolation in 
the sputum (73 patients) with the rest of the group, their 
differential characteristics are fewer admissions over the 
previous year (P=0.01), lesser presence of sputum increase 
(P=0.008) and sputum purulence (P=0.02), lesser presence of 
cor pulmonale (P=0.02), less depression (P=0.03), less need 
of continuous positive airway pressure (P=0.003), shorter 
hospital stays (P=0.02), lower CRP values (P=0.04), and 
fewer associated comorbidities (P=0.046). As for severity of 
the COPD, they had a lower FVC in milliliter (P=0.03).
We analyzed the characteristics of patients according to the 
results of the sputum culture, by grouping these results according 
to the isolation of P. aeruginosa or Enterobacteriaceae (group 1); 
S. pneumoniae, H. influenzae, or M. catharralis (group 2); or 
nPPM (group 3). The results are presented in Table 4. COPD 
patients in group 1 had significantly more admission in the 
previous year, increased sputum, and more heart failure; while 
those in group 2 had more osteoporosis (P,0.05).
Discussion
Our study shows that COPD patients hospitalized for an AE-
COPD with P. aeruginosa isolation present greater severity 
of their disease, with worse levels of respiratory parameters 
as measured with the predicted %FEV
1
 after bronchodilata-
tion, greater dyspnea by the mMRC scale, higher scores in the 
BODEx index, and more hospitalizations over the previous 
year. The isolation of S. pneumoniae, in turn, is associated 
Table 4 Characteristics of patients according to sputum culture groups
Comorbidities Total (n=536) Group 1 (n=45) Group 2 (n=43) Group 3 (n=73) P-value
Admission in the previous year 121 (75.2) 39 (86.7) 34 (79.1) 48 (65.8) 0.030
First admission for ae-COPD 28 (17.4) 3 (10.7) 8 (28.6) 17 (60.7) 0.067
lTOT 79 (49.1) 24 (53.3) 19 (44.2) 36 (49.3) 0.691
Antibiotics previous admission 53 (32.9) 18 (40) 12 (27.9) 23 (31.5) 0.455
Corticoids previous admission 38 (23.6) 13 (28.9) 9 (20.9) 16 (21.9) 0.612
Increased sputum 135 (84.9) 41 (93.2) 38 (90.5) 56 (76.7) 0.027
Change in expectoration 139 (87.4) 42 (95.5) 38 (90.5) 59 (80.8) 0.054
heart failure 56 (34.8) 23 (51.1) 13 (30.2) 20 (27.4) 0.024
Cerebrovascular disease 28 (17.5) 11 (24.4) 8 (18.6) 9 (12.5) 0.248
Chronic renal failure 24 (14.9) 5 (11.1) 9 (20.9) 10 (13.7) 0.402
Cor pulmonale 45 (28) 16 (35.6) 15 (33.3) 14 (31.1) 0.078
Osa 22 (13.7) 10 (22.2) 4 (9.3) 8 (11) 0.139
neoplasm 21 (13) 4 (8.9) 5 (11.6) 12 (16.4) 0.472
Depression 32 (19.9) 10 (22.2) 13 (30.2) 9 (12.3) 0.059
Osteoporosis 32 (19.9) 8 (17.8) 14 (32.6) 10 (13.7) 0.045
Peripheral arterial disease 24 (14.9) 4 (8.9) 10 (23.3) 10 (13.7) 0.155
Notes: Data presented as absolute (relative) frequencies or mean (standard deviation). Group 1: Pseudomonas aeruginosa or Enterobacteriaceae. group 2: Streptococcus 
pneumoniae or Haemophilus influenzae or Moraxella catharrhalis. Group 3: non-potential pathogen microorganisms.
Abbreviations: AE-COPD, acute exacerbation of chronic obstructive pulmonary disease; LTOT, long-term oxygen therapy; OSA, obstructive sleep apnea–hypopnea syndrome.
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with more associated comorbidities, assessed by the number 
of comorbidities or with the Charlson index. Finally, patients 
with isolation of enterobacteria are younger, have less func-
tional impairment, and more use of non-invasive mechanical 
ventilation similar to continuous positive airway pressure. 
Thus, we have noted that the diseases associated to COPD dif-
fer depending on the microorganism isolated in the sputum.
These data are relevant for clinical practice, as they help 
decide the empirical antibiotic treatment for each kind of 
patients in those AE-COPD that require hospitalization. 
Presently, according to clinical practice guidelines,15,16 it is 
advised to determine the antibiotic treatment for AE-COPD 
depending on the patient’s comorbidities, since they affect 
the risk of therapeutic failure. According to our results, this 
comorbidity varies depending on the etiology of the bacte-
rial exacerbation.
Only a recent study has described the identification of 
bacterial etiology in relation to the clinical characteristics of 
patients. Miravitlles et al10 identified factors independently 
associated with bacterial growth, such as current smoking 
and H. influenzae; longer periods between exacerbations and 
S. pneumoniae; or decrease in FEV
1
 and P. aeruginosa.
Traditionally, bacterial identification has been defined 
depending on the severity of the COPD, since S. pneumoniae, 
H. influenzae, and M. catharralis are isolated in patients 
with predicted FEV
1 
.50%, and Enterobacteriaceae and 
P. aeruginosa in those with FEV
1
 ,50%, as verified by 
Miravitlles et al10 and Eller et al.22
Other authors have also identified a greater growth of 
P. aeruginosa in patients with lower levels of FEV
1
,23,24 and 
other factors of greater severity of COPD.25,26 García-Vidal 
et al27 defined the BODEx index, the number of hospital 
admissions in the previous year, treatment with corticoids, 
and prior isolation of P. aeruginosa as risk factors.
COPD is a heterogeneous disease that requires categorizing 
patients in subgroups in order to optimize their management 
in clinical practice, identifying traits of the disease with clini-
cal significance. Likewise, there are exacerbation subtypes 
depending on the number of previous days with symptoms,28 
or by etiology. There have been attempts to typify different 
exacerbation subtypes through biomarkers. Bafadhel et al29 
described three types of exacerbation: bacterial, viral, and 
eosinophilic. Among the bacterial causes, comorbidity might 
orient us toward a certain etiological agent.
On bacterial etiology the conventional study of sputum 
plays an important role. It is the simplest and most accessible 
method for diagnosing the etiology of bacterial infections in 
AE-COPD. Nevertheless, its value is debatable in some cases 
due to bacterial colonization in certain patients,30 and to the 
increasing importance of other, non-bacterial etiologies such 
as respiratory viruses, that are isolated in more than 50% of 
cases, frequently associated with bacteria.31 Most guidelines 
recommend conducting a sputum culture in case of severe 
exacerbation, the presence of risk factors for multiresistant 
bacteria, or if there is therapeutic failure.16,17,32,33
Most studies have focused on the risk factors for growth 
in the sputum culture for P. aeruginosa, while obtaining 
similar results to ours about other microorganisms (although 
with better results in obtaining valid sputum samples from 
patients admitted with AE-COPD, as they induced sputum). 
For instance, a study similar to ours27 included 188 patients, 
obtaining quality sputum samples from 119 subjects (63%). 
Of the quality cultures, 55% were for PPM and the remaining 
45% for nPPM, identical to our results.
One of the factors predicting growth of PPM in cultures is 
the purulence of the sputum, but it must be observed by clini-
cians, since it is less reliable when reported by the patients 
themselves.34 This has led researchers to look for other 
predictors of purulence in the sputum, such as FEV
1
 ,35% 
and body mass index ,22.35 Also, Larsen et al23 identified 
the number of neutrophils in peripheral blood as a predictor 
of growth in the sputum. Roche et al24 associated it to the 
presence of bronchiectasis, chronic home oxygen therapy, 
and lower levels of FEV
1
%. Recently, Bafadhel et al36 had 
shown that patients with persistently positive sputum samples 
have particularly severe neutrophilic airway inflammation 
and poor clinical outcomes, and the H. influenzae was the 
most commonly isolated pathogen.
Thus, for instance, the presence of Anthonisen’s criteria 
(type I) in patients with decreased lung function has been 
described as indicative of antibiotic treatment.37 Nevertheless, 
recent studies point out that purulence in the sputum remains 
the most important factor.9
Finally, we observed that the most frequently isolated 
microorganism was P. aeruginosa (30.7%), followed 
by S. pneumoniae (26.1%), Enterobacteriaceae (20.4%), 
H. influenzae (15.9%), and M. catharralis (6.8%). We did not 
encountered any patient with Staphylococcus aureus. Other 
authors in Spain have also identified a similar rate.25,27
Our study has several limitations. First, the reduced 
number of women, similar to other studies conducted in 
Spain, probably due to its late entry to smoking in Spain. 
Second, most of the patients included in the study had been 
hospitalized in Internal Medicine Services, and probably 
presented more associated pathologies than those admit-
ted to Pneumology departments. In Spain, 40%–50% of 
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COPD exacerbations are attended to in Internal Medicine 
Services, which usually care for older patients with more 
comorbidities;38 however, the data about mortality and read-
missions shown in our study are similar to those obtained by 
another paper, studying 1,200 patients admitted to a variety 
of services and hospitals.39 Also, the difficulty of identifying 
the etiology of exacerbation through the sputum has been 
pointed out before. In addition, a significant percentage of 
the patients were already being treated with antibiotics prior 
to their hospitalization, which hampers studying their case 
through conventional sputum samples. A final limitation is 
that computed tomography was not undertaken as part of 
the study protocol, so we are not in a position to determine 
whether the presence of bronchiectasis was an important 
cofactor in these subjects.
In summary, the etiology of bacterial infections in AE-
COPD can be implied through characteristics of patients 
such as their associated comorbidities. P. aeruginosa, for 
instance, is associated with a greater severity of COPD itself; 
S. pneumoniae, with a disease not as severe but with a longer 
time of evolution, more comorbidities, and more vascular risk 
factors; and Enterobacteriaceae are associated with younger 
patients in need of continuous positive airway pressure.
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